Dry Powder Nasal Drug Delivery: opportunities and challenges

Dry Powder Nasal Drug Delivery: opportunities and challenges

March 11, 2016

Do you want to learn how to formulate and use dry powder formulations for intranasal drug delivery?

Aedestra and the Woolcock Institute at the University of Sydney have just published an article on DDIP on that very subject. Here is an extract of the publication:

Purpose: To discuss the challenges and opportunities for dry powder nasal medications and to put this in to perspective by evaluating and characterizing the performance of the Teijin- bechlomethasone diproprionate dry powder nasal inhaler; providing a baseline for future nasal products development.
Methods: The aerosol properties of the formulation and product performance of Teijin powder intranasal spray were assessed, with a particular focus on particle size distribution (laser diffraction), powder formulation composition (confocal Raman microscope) and aerosol performance data (British Pharmacopoeia Apparatus E cascade impactor, aerosol laser diffraction).
Results: Teijin Rhinocort® (beclometasone dipropionate, BDP) dry powder spray formulation is a simple blend of one active ingredient, BDP with hydroxypropylcellulose (HPC) carrier particles and a smaller quantity of lubricants (stearic acid and magnesium stearate). The properties of the blend are mainly those of the carrier (Dv50 = 98 ± 1.3 μm). Almost the totality of the capsule fill weight (96.5%) was emitted with 8 actuations of the device. Using the pharmacopeia suggested nasal chamber deposition apparatus attached to an Apparatus E impactor. The BDP main site of deposition was found to be in the nasal expansion chamber (90.2 ± 4.78%), while 4.64 ± 1.38% of the BDP emitted dose was deposited on Stage 1 of the Apparatus E.
Conclusions: The Teijin powder nasal device is a simple and robust device to deliver pharmaceutical powder to the nasal cavity, thus highlighting the robustness of intranasal powder delivery systems. The large number of actuations needed to deliver the total dose (eight) should be taken in consideration when compared to aqueous sprays (usually 2 actuations), since this will impact on patient compliance and consequently therapeutic efficacy of the formulation.

You can download the full text of the reference here:
http://www.tandfonline.com/doi/abs/10.3109/03639045.2016.1160110

Aedestra is a product development company in the field of inhaled drug product.  We make developing inhaled products easy, so you can focus on delivery. We drive initiatives; you realise opportunities. We can help you develop the right product in the right way by providing strategic and technical expertise: reducing cost, time and risk. Get in touch now to expand and develop your inhaled portfolio.